Vomiting: What Could Be Causing It

The Vomiting Reflex: How the Brain Coordinates Emesis

The act of vomiting is not a single event but a coordinated neuromuscular sequence orchestrated by the nucleus tractus solitarius (NTS) and the nearby chemoreceptor trigger zone (CTZ) in the area postrema of the medulla. Afferent signals arrive from four major pathways: vagal and sympathetic nerves from the gastrointestinal tract, vestibular input from the inner ear, direct chemical stimulation of the CTZ by circulating toxins or drugs, and cortical input from higher brain centers responding to pain, memory, or anxiety.

Once the vomiting center threshold is reached, a stereotyped motor pattern activates. The diaphragm contracts downward, the abdominal wall muscles compress the stomach, the lower esophageal sphincter relaxes, and the glottis closes to protect the airway 1. This sequence explains why vomiting from very different causes (motion sickness versus chemotherapy versus bowel obstruction) shares the same physical mechanics despite originating from completely different triggers.

Understanding these pathways matters clinically because antiemetic drugs target specific receptor systems along specific pathways. Ondansetron blocks serotonin 5-HT3 receptors on vagal afferents. Promethazine blocks histamine H1 receptors in the vestibular system. Metoclopramide acts on dopamine D2 receptors in the CTZ 2.

Gastrointestinal Causes: The Most Common Category

GI pathology accounts for more than 50% of vomiting presentations in emergency departments. Acute viral gastroenteritis leads the list. Norovirus alone causes an estimated 19-21 million illnesses annually in the United States, according to CDC surveillance data 3. Onset is abrupt. Vomiting begins 12-48 hours after exposure and typically resolves within 72 hours without specific therapy.

Food poisoning from bacterial toxins (Staphylococcus aureus, Bacillus cereus) produces vomiting within 1-6 hours of ingestion. The short incubation period distinguishes toxin-mediated illness from infectious gastroenteritis.

Beyond infections, structural GI problems cause vomiting through mechanical or functional obstruction:

• Small bowel obstruction (SBO) produces bilious vomiting, colicky abdominal pain, and distension. Adhesions from prior surgery account for 60-75% of SBO cases in developed countries 4.
• Gastroparesis causes nausea and vomiting of partially digested food hours after meals. A 2018 systematic review reported that 30-50% of patients with type 1 diabetes of more than 10 years duration have delayed gastric emptying on scintigraphy 5.
• Acute pancreatitis produces severe epigastric pain radiating to the back with persistent vomiting. Serum lipase greater than three times the upper limit of normal confirms the diagnosis with 95% specificity 6.
• Acute appendicitis classically presents with periumbilical pain migrating to the right lower quadrant, followed by nausea and vomiting in 60-70% of cases.

Peptic ulcer disease deserves separate mention. A Helicobacter pylori-positive ulcer or NSAID-induced ulcer may produce vomiting when gastric outlet edema narrows the pyloric channel. Endoscopy confirms the diagnosis and guides eradication therapy.

Medication and Substance-Induced Vomiting

Drug-induced nausea and vomiting is the second most common category in outpatient settings. Chemotherapy-induced nausea and vomiting (CINV) affects 60-80% of patients receiving highly emetogenic regimens such as cisplatin 7. The American Society of Clinical Oncology (ASCO) guideline recommends triple antiemetic prophylaxis (NK1 antagonist plus 5-HT3 antagonist plus dexamethasone) for high-emetic-risk chemotherapy, which reduces acute CINV to below 30% 8.

Opioids stimulate the CTZ directly and also slow gastric motility. A meta-analysis of 16 randomized trials found that opioid-induced nausea and vomiting occurred in 25-30% of postoperative patients receiving morphine 9.

Other frequently implicated medications include:

• Selective serotonin reuptake inhibitors (SSRIs), especially in the first 1-2 weeks of therapy
• Antibiotics, particularly erythromycin and metronidazole
• Digoxin at supratherapeutic levels (toxicity threshold: serum level above 2.0 ng/mL)
• Iron supplements taken on an empty stomach
• GLP-1 receptor agonists such as semaglutide and tirzepatide, where nausea occurs in 40-44% of patients during dose escalation per the STEP-1 trial (N=1,961) 10

Cannabis hyperemesis syndrome (CHS) has emerged as an increasingly recognized cause in chronic cannabis users. Compulsive hot bathing provides temporary relief. The diagnosis requires cessation of cannabis with documented resolution of symptoms 11.

Pregnancy-Related Nausea and Vomiting

Nausea and vomiting of pregnancy (NVP) affects 50-80% of pregnant individuals, typically between weeks 6 and 16 of gestation 12. The condition exists on a spectrum. Mild NVP is self-limited. Hyperemesis gravidarum (HG), defined as persistent vomiting with greater than 5% pre-pregnancy weight loss, ketonuria, and electrolyte disturbances, affects 0.3-3% of pregnancies and may require hospitalization.

The American College of Obstetricians and Gynecologists (ACOG) recommends a stepwise approach: dietary modification and ginger (250 mg four times daily) as first-line therapy, then doxylamine 12.5 mg plus pyridoxine 10 mg (Bonjesta) for persistent symptoms, followed by ondansetron 4 mg every 8 hours for refractory cases 13.

A critical clinical point: new-onset vomiting after 20 weeks of gestation should raise concern for preeclampsia, acute fatty liver of pregnancy, or HELLP syndrome rather than typical NVP.

Central Nervous System and Vestibular Causes

Raised intracranial pressure (ICP) produces vomiting that is classically described as "projectile" and worst in the morning. Causes include brain tumors, intracranial hemorrhage, hydrocephalus, and idiopathic intracranial hypertension. The combination of vomiting plus headache plus papilledema on fundoscopy is an emergency requiring urgent neuroimaging 14.

Vestibular causes include:

• Benign paroxysmal positional vertigo (BPPV): brief episodes of vertigo and nausea triggered by head position changes. The Dix-Hallpike maneuver confirms the diagnosis.
• Vestibular migraine: episodic vertigo with nausea lasting 5 minutes to 72 hours, often without headache. Affects approximately 1% of the general population 15.
• Meniere disease: the classic triad of vertigo, tinnitus, and hearing loss with associated nausea and vomiting.
• Labyrinthitis and vestibular neuritis: sudden-onset sustained vertigo with vomiting lasting days.

Motion sickness activates vestibular-cerebellar pathways and responds well to anticholinergics (scopolamine patch) or antihistamines (meclizine 25 mg).

Metabolic, Endocrine, and Systemic Causes

Several metabolic derangements trigger vomiting through direct CTZ stimulation:

Diabetic ketoacidosis (DKA) causes vomiting in over 70% of presentations. Circulating ketones and acidosis stimulate the area postrema directly. Vomiting may be the presenting complaint before the classic triad of polyuria, polydipsia, and Kussmaul respirations becomes apparent 16.

Uremia from advanced chronic kidney disease or acute kidney injury produces nausea and vomiting when blood urea nitrogen exceeds approximately 60-80 mg/dL. Uremic toxins accumulate and stimulate the CTZ.

Adrenal crisis (acute adrenal insufficiency) presents with vomiting, hypotension, and hyponatremia. This is life-threatening without immediate IV hydrocortisone 100 mg.

Hypercalcemia above 12 mg/dL commonly produces nausea, vomiting, constipation, and confusion. Primary hyperparathyroidism and malignancy account for over 90% of cases.

Hyponatremia below 125 mEq/L causes nausea; levels below 120 mEq/L frequently cause vomiting and may progress to seizures and cerebral edema.

Dr. Michael Camilleri, a gastroenterologist at Mayo Clinic, has noted: "The clinician's first job is to determine whether vomiting represents a GI problem, a systemic metabolic disturbance, or a CNS process. The timing, associated symptoms, and basic labs almost always point you in the right direction" 17.

Cyclic Vomiting Syndrome

Cyclic vomiting syndrome (CVS) is a functional disorder characterized by recurrent, stereotypical episodes of intense vomiting separated by symptom-free intervals. The Rome IV criteria require at least two episodes in the prior 6 months with each episode lasting less than one week 18. Episodes often begin in the early morning hours and may produce 6-12 emeses per hour at peak.

CVS affects approximately 2% of school-age children and an estimated 0.5-1% of adults. It shares pathophysiologic overlap with migraine headache; family history of migraine is present in 50-70% of pediatric CVS patients. Tricyclic antidepressants (amitriptyline 1 mg/kg/day) reduce episode frequency by 50-70% in prospective studies 19.

Diagnostic Approach: History, Examination, and Testing

The diagnostic evaluation of vomiting depends on acuity, severity, and associated features. A structured approach includes:

History: Timing relative to meals (early = gastric; delayed = gastroparesis or obstruction), character of vomitus (bilious = distal to ampulla of Vater; feculent = distal obstruction), associated symptoms (fever suggests infection; weight loss suggests malignancy or gastroparesis), medications, pregnancy status, and substance use.

Physical examination: Assess hydration status (mucous membranes, skin turgor, capillary refill), abdominal findings (distension, tenderness, high-pitched bowel sounds), and neurological signs (papilledema, nystagmus, focal deficits).

First-line laboratory tests:

• Complete metabolic panel (electrolytes, glucose, BUN/creatinine, liver enzymes, lipase)
• Urine pregnancy test in reproductive-age individuals
• Urinalysis for ketones and specific gravity

Imaging:

• Abdominal X-ray (supine and upright) if obstruction is suspected; air-fluid levels and dilated loops confirm SBO
• CT abdomen/pelvis with IV contrast for suspected appendicitis, pancreatitis, or unclear acute abdomen
• Brain MRI or CT head for suspected raised ICP

Specialized testing:

• Gastric emptying scintigraphy (4-hour solid-phase study) for suspected gastroparesis; retention of more than 10% at 4 hours confirms delayed emptying per the American Neurogastroenterology and Motility Society consensus 20
• Upper endoscopy for persistent vomiting with dysphagia, weight loss, or GI bleeding

The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) recommends that clinicians "avoid routine imaging in children with acute vomiting unless red-flag symptoms such as bilious emesis, abdominal distension, or bloody stool are present" 21.

Treatment: Rehydration and Targeted Antiemetics

The management of vomiting has two concurrent goals: correct fluid and electrolyte deficits, and suppress the vomiting reflex while addressing the underlying cause.

Fluid resuscitation: Oral rehydration solution (ORS) is first-line for mild-to-moderate dehydration. The WHO formulation (75 mEq/L sodium, 75 mmol/L glucose) reduces the need for IV fluids by 33% compared to standard clear liquids in randomized trials 22. Small, frequent sips (5-10 mL every 5 minutes) succeed more often than large boluses. IV normal saline or lactated Ringer's solution is indicated for severe dehydration, inability to tolerate oral intake, or hemodynamic instability.

Antiemetic selection by mechanism:

| Pathway | Drug | Dose | Best For | |---------|------|------|----------| | 5-HT3 antagonist | Ondansetron | 4-8 mg PO/IV q8h | Gastroenteritis, postop, CINV | | D2 antagonist | Metoclopramide | 10 mg PO/IV q6h | Gastroparesis, migraine | | NK1 antagonist | Aprepitant | 125 mg PO day 1 to 80 mg days 2-3 | Highly emetogenic chemo | | H1 antagonist | Meclizine | 25 mg PO q6h | Vestibular causes | | Anticholinergic | Scopolamine patch | 1.5 mg TD q72h | Motion sickness |

Cause-specific therapy: Bowel obstruction requires nasogastric decompression and surgical consultation. DKA requires insulin infusion and aggressive IV fluids. Raised ICP requires emergent neurosurgical evaluation. Medication-induced vomiting requires dose adjustment or drug substitution.

Red Flags: When Vomiting Is an Emergency

Certain features demand immediate evaluation:

• Hematemesis (bloody or coffee-ground emesis) suggesting upper GI hemorrhage
• Bilious vomiting in an infant (malrotation with midgut volvulus until proven otherwise)
• Vomiting with severe headache, neck stiffness, or altered consciousness (meningitis, subarachnoid hemorrhage, or raised ICP)
• Projectile vomiting in a 3-6 week old infant (pyloric stenosis; ultrasound confirms pyloric muscle thickness greater than 3 mm)
• Vomiting after head trauma (raised ICP or concussion)
• Vomiting with chest pain or diaphoresis (inferior myocardial infarction can present as nausea and vomiting in 30-40% of cases)
• Signs of severe dehydration: sunken eyes, absent tears, prolonged capillary refill above 3 seconds, oliguria

A retrospective study of 2,406 ED presentations for vomiting found that 8.3% had a surgical diagnosis requiring operative intervention, most commonly appendicitis (3.1%), SBO (2.4%), and cholecystitis (1.8%) 23.

Home Management and Prevention

For uncomplicated viral gastroenteritis in otherwise healthy adults, home management is appropriate. Evidence-supported strategies include:

• Sip 30-60 mL of oral rehydration solution every 15 minutes for the first 4 hours
• Resume a normal diet as tolerated once vomiting subsides; the former "BRAT diet" recommendation has been abandoned by the AAP as unnecessarily restrictive 24
• Ginger (250 mg capsules four times daily) reduces nausea severity by 40% compared to placebo in a double-blind crossover trial of chemotherapy patients 25
• Avoid solid food only during active vomiting episodes; prolonged fasting worsens ketosis and delays recovery

Prevention of recurrent vomiting depends on the underlying cause. Patients with gastroparesis benefit from small, low-fat, low-fiber meals eaten 4-6 times daily. Those with cyclic vomiting syndrome should identify and avoid personal triggers (sleep deprivation, fasting, emotional stress, menstruation) and consider prophylactic amitriptyline or topiramate.

Patients on GLP-1 receptor agonists experiencing dose-escalation nausea should slow their titration schedule. The STEP-1 protocol escalated semaglutide every 4 weeks; extending intervals to 6-8 weeks during problematic transitions reduces GI side effects without compromising long-term weight outcomes 10.